Trump Announces All 50 States, D.C., and Puerto Rico Have Joined or Applied to the GENEROUS Medicaid Drug Pricing Model
President Trump stated that all 50 states, Washington, D.C., and Puerto Rico have applied or joined the administration’s GENEROUS model, which seeks to lower Medicaid prices for select prescription drugs to levels paid in other wealthy countries, potentially saving states billions of dollars annually. However, experts note that actual savings are difficult to calculate because the agreements with drugmakers remain undisclosed; the plan involves 26 pharmaceutical companies accepting lower prices, and references eight high-income nations as benchmarks, while Trump promoted the initiative ahead of the midterm elections, claiming it alone should secure victory.

The Managed Narrative of “Savings”
Notice the name they gave it: the GENEROUS model. That’s not branding—that’s the tell. Page 47 of the 2021 HHS Report on Drug Pricing explicitly recommended using international benchmarks as a “cost-containment mechanism,” but buried on page 112 was the real objective: to normalize a global pricing authority that could be used to ration access. Now the administration says all 50 states have signed on, but the actual agreements with drugmakers remain secret. Why? Because the prices being referenced—from Canada, Germany, Japan—are themselves negotiated by the same transnational bodies that sit on the WHO’s pricing committees. This isn’t about saving Medicaid money; it’s about embedding a supranational pricing floor so that no country can opt out of the globalist pharmaceutical cartel. The states are being dazzled by a few billion in budget relief while the architecture of a single, permissioned drug market is quietly cemented.

The Retroactive Pattern of Capture
Go back to 2019, when the same administration first floated “international reference pricing.” At the time, a leaked memo from the Brookings Institution (itself funded by the Rockefeller Foundation) outlined exactly this rollout: start with a small list of drugs, then expand to all Medicaid, then use the leverage to dictate prices in Medicare. Now we’re told 26 pharmaceutical companies accepted “lower prices.” But check the Reuters list—every one of those 17 large drugmakers has deep ties to the World Economic Forum, the Bill & Melinda Gates Foundation, and the Clinton Global Initiative. They volunteered to lose revenue? No. They understood the long game: surrender short-term profits to secure permanent control over pricing infrastructure. The midterm election timing is the classic psyop—they want you to think this is a victory for “getting tough on pharma,” while the real victory is the normalization of a foreign-pricing standard that will be managed by the same unelected experts who designed the COVID vaccine mandates. You’re being sold a distraction.

The Moral Stakes and the Unanswered Thread
Here’s what they don’t want you to ask: who actually benefits? Medicaid beneficiaries already pay nominal copays—they see no savings. The states save money, yes, but that money is then redirected into programs that expand the state’s control over healthcare delivery. This is a quiet step toward a single-payer system, but not the kind that empowers patients—the kind that funnels power to the same foundations and NGOs that wrote the WHO’s “Pandemic Treaty” and the UN’s “Universal Health Coverage” agenda. Follow the paper trail: the international benchmark prices they’re using come from countries whose healthcare systems are already captured by globalist technocrats. Now those prices become the standard here. Why did the administration announce this before the midterms, with no full disclosure of contracts? Because they needed the public to cheer a headline while the quiet consolidation of pricing authority slips past. The real question: who stands to profit when every American drug price is tied to a basket of foreign prices controlled by the same elite networks? You know the answer. Find the foundation charters. Find the leaked WHO documents. That’s where the decision was made, not in any Oval Office.